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Summary
Background: Osteoarthritis (OA) is frequently treated only during periods of ﬂare, in which rapid onset of analgesia is the outcome target.
Objective: To assess an acute pain model of knee OA in ﬂare.
Methods: In a multicenter, randomized, double-blind, controlled study, 530 patients aged 50 years received valdecoxib 10 mg qd (n¼ 212),
rofecoxib 25 mg qd (n¼ 208), or placebo (n¼ 110). Pain intensity (PI) was measured on a visual analog scale (VAS) at baseline after a 10-min
walk. Patients took their ﬁrst dose of study medication, rested for 20 min, then measured their PI VAS at 0.5, 1, 1.5, 2, 3, 4, 5, and 6 h, each
time following a 10-min walk.
Results: PI VAS differences (PID) were signiﬁcantly greater vs placebo both with valdecoxib and rofecoxib (P< 0.05) beginning as early as
3 h (intent-to-treat population). The percentage of patients with analgesia onset from 4 h was signiﬁcantly higher with both valdecoxib (55%)
and rofecoxib (56%) relative to placebo (40%). Median time to ﬁrst onset of analgesic was shorter with both valdecoxib and rofecoxib com-
pared with placebo (P¼ 0.104 vs valdecoxib; P¼ 0.036 vs rofecoxib).
Conclusions: This acute pain model of knee OA ﬂare detected signiﬁcant pain relief with agents known to relieve pain in OA and placebo
within hours after the ﬁrst treatment dose, allowing assessment of pain relief within hours rather than days or weeks when evaluating analgesic
efﬁcacy in OA. This model is undergoing further study to determine optimal walk times, distances, and rates to maximize its sensitivity.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) symptoms are episodic, and the disease
is frequently treated only during periods of ﬂare. On aver-
age, patients with OA are treated for only 94 days per
year1. Most traditional studies involving OA patients mea-
sure efﬁcacy after several weeks to months of treatment.
In patients experiencing a ﬂare of painful symptoms, rapid
onset of pain relief would be advantageous; accordingly, it
would be useful to measure the onset of analgesic action
shortly following medication. A rapid onset of analgesia in
patients with OA ﬂare may help to limit worsening of chronic
pain resulting from peripheral and central sensitization2.
1The study was sponsored by Pﬁzer Global Pharmaceuticals and
Pharmacia Corporation.
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the onset of analgesia in patients experiencing an OA ﬂare
of the knee3. In this model, treatment is initiated following
a period of induced pain (ﬂare) to evaluate acute pain
response. Pain intensity (PI) is assessed using the visual
analog scale (VAS) during the ﬁrst 6 h following medication.
Each pain assessment is made following a 10-min walk to
more closely simulate the clinically relevant pain that is
characteristically seen in patients with OA.
In previous acute pain studies, following dental extraction
categorical mean PI difference (PID) and pain relief scores
were similarly signiﬁcantly improved vs placebo with valde-
coxib 40 mg, and with an oxycodone 10 mg/acetaminophen
1000 mg combination4. In another dental pain model study,
median time to onset in responders following a valdecoxib
dose of 10 mg was 39 min, statistically signiﬁcantly different
from placebo5. Signiﬁcantly improved PID scores and pain
relief scores with rofecoxib 50 mg vs placebo were
achieved 45 min after the ﬁrst dose6,7. There is currently
no published information comparing valdecoxib 10 mg
with rofecoxib 25 mg in OA patients, or assessing onset
of analgesia following medication on day 1 in patients with
OA in ﬂare, using PI after walking.111
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identically designed studies comprised of a 24-h ﬂare model
assessment phase, and a 2-week extension, which com-
pared treatment with the cyclooxygenase (COX)-2 speciﬁc
inhibitors, valdecoxib and rofecoxib, and placebo. Although
valdecoxib is approved for the relief of signs and symptoms
of OA6e10, the United States Food and Drug Administration,
in April 2005, requested that the manufacturer (Pﬁzer, Inc.)
suspend sales of valdecoxib, due primarily to an increased
risk of rare, but potentially severe cutaneous adverse reac-
tions11. Rofecoxib, also indicated for the relief of the signs
and symptoms of OA, was withdrawn from the market
voluntarily by its manufacturer due to concerns regarding
cardiovascular risk. Patients with knee OA ﬂare were ran-
domized to receive their ﬁrst dose of double-blind treatment
with valdecoxib 10 mg, rofecoxib 25 mg, or placebo. Onset
of analgesia was measured in the ﬂare model assessment
during the ﬁrst 6 h, following a series of 10-min walks. In
study 1, the OA ﬂare model failed to show any treatment
differences vs placebo on day 1; this may have been a result
of differing levels of familiarity and application of the newly
designed study methodology in some of the investigative
sites. This paper, which focuses on the ﬂare model method-
ology, presents the detailed results observed in study 2
utilizing the modiﬁed analgesic model.
Methods
The protocol for this multicenter, randomized, double-
blind, double-dummy, placebo-controlled study was
reviewed by the appropriate Institutional Review Boards,
and all patients provided written informed consent before
entering the study. The trial was conducted in accordance
with the ethical principles that have their origins in the
Declaration of Helsinki.
PATIENTS
Patients were aged at least 45 years, and had OA of the
knee according to the American College of Rheumatology
criteria12. They were required to have a Functional Capacity
Classiﬁcation between I and III at the screening assess-
ment13. In patients with bilateral knee OA, the knee with
the most severe symptoms was deﬁned as their index joint.
Eligible patients had OA in a ﬂare state at the baseline
assessment. Two categories of ﬂare were described.
Patients who had previously been receiving nonsteroidal
anti-inﬂammatory drugs (NSAIDs) or analgesic therapy for
their OA (Category 1 patients) discontinued their treatment
for at least 2 days or a minimum of ﬁve half-lives of the
agent, whichever was greater, prior to the baseline visit.
An OA ﬂare state was deﬁned as a patient’s and physician’s
global assessment of arthritis activity of ‘‘fair’’, ‘‘poor’’, or
‘‘very poor’’ at the baseline visit; one subject was rated
‘‘good’’ at baseline. In addition, patients were required to
have 3 of the following four criteria when comparing
screening to baseline: patient’s assessment of arthritis
pain VAS walking on a ﬂat surface at baseline of
40 mm; an increase of 2 points in Lequesne OA severity
index, a validated algofunctional assessment instrument14;
an increase of 1 grade in the patient’s global assessment
of arthritis; and an increase of 1 grade in the physician’s
global assessment of arthritis. In patients who had not
previously been receiving NSAID or analgesic therapy
and whose OA was not controlled (Category 2 patients),
an OA ﬂare state was deﬁned as having 3 of the followingfour criteria during the baseline visit: patient’s assessment
of arthritis pain VAS of 40 mm; a Lequesne OA severity
index of 7; patient’s global assessment of arthritis of
‘‘poor’’ or ‘‘very poor’’; and physician’s global assessment
of arthritis of ‘‘poor’’ or ‘‘very poor’’.
Patients were excluded from the trial if they
(1) Had been diagnosed with inﬂammatory arthritis or
acute joint trauma of the index joint;
(2) Had a history of malignancy, active gastrointestinal
disease, chronic or acute renal/hepatic disorders, or
signiﬁcant coagulation disorders;
(3) Had abnormal screening laboratory values exceeding
1.5 times the upper limit of normal for either aspartate
aminotransferase or alanine aminotransferase, a se-
rum creatinine 2.0 mg/dL, or any other clinically sig-
niﬁcant laboratory abnormality within 14 days prior to
the baseline visit;
(4) Had received oral, intramuscular, or intra-articular
corticosteroids within 8 weeks, or intra-articular
hyaluronic acid in the index joint within 6 months of
study drug administration;
(5) Had taken anticoagulants, NSAIDs, COX-2 speciﬁc
inhibitors, or analgesic agents. However, patients
were allowed to use acetaminophen (1000 mg prn,
up to 4 g/day) as rescue analgesia up until 24 h be-
fore each arthritis assessment.
(6) Had taken methotrexate, gold salts, penicillamine,
antimalarials, sulfasalazine, azathioprine, cyclospor-
ine, leﬂunomide, etanercept, or inﬂiximab during the
screening period. Glucosamine or chondroitin sulfate
was prohibited during the screening period unless the
patient had been on a stable dose for at least 3
months before enrolling in the study.
Patients taking low-dose aspirin (325 mg/day) for
nonarthritic reasons were allowed to continue their aspirin
regimen for the duration of the study. Antiplatelet agents,
such as clopidrogel or ticlopidine, were permitted for
patients on a stable dose for at least 30 days prior to the
screening visit.
SCREENING ASSESSMENTS
At a screening visit between day 14 and day 0, OA
assessments were taken. In the assessment of the primary
outcome, ‘‘Pain in the Index Knee’’, patients evaluated their
pain on a 100-mm VAS, where 0¼ no pain and 100¼most
severe pain, in response to the question, ‘‘How much pain
are you having because of the OA in your index knee?’’
ASSESSMENT
Baseline OA assessments on day 1
OA assessments were taken at baseline, and an assess-
ment of ﬂare was made, as deﬁned above, to determine
eligibility for enrollment into the study. The Western Ontario
and McMaster Universities OA Index (WOMAC), a self-
administered patient questionnaire, was used prior to any
other OA assessments, and evaluated patients’ ability to
perform daily activities based on their physical function,
pain, and stiffness15. WOMAC total domain scores using
a Likert scale range from 0 to 96, pain scores range from
0 to 20, stiffness scores range from 0 to 8, and physical
function scores range from 0 to 68. For each WOMAC OA
Index, lower scores were considered to be better.
1113Osteoarthritis and Cartilage Vol. 14, No. 11Fig. 1. Schedule of PI assessments in the clinic.Measurement of onset of analgesia with
walking on day 1
Eligible patients with OA ﬂare of the knee were random-
ized 2:2:1 in the order that they were enrolled to receive
their ﬁrst dose of valdecoxib 10 mg, rofecoxib 25 mg, or
placebo in a double-blind, double-dummy design. Patientswere asked to walk on a ﬂat surface for 10 min, after
which they assessed their baseline PI VAS and took their
ﬁrst dose of study medication (time 0) (Fig. 1). Patients
rested for 20 min, then completed the patient’s assess-
ment of OA pain VAS at 0.5, 1, 1.5, 2, 3, 4, 5, and 6 h
after study drug administration, each time following a
10-min walk.N=530
Patients randomized and 
included in the 
 ITT population  
N=212
Valdecoxib 10 mg qd 
N=208
Rofecoxib 25 mg qd 
N=110
Placebo
 n=33 Excluded from PP 
(1)   Major protocol violation                    5 
  (2)   Did not perform all walks
         on Day 1                                            19  
  (3)   No predose pain assessment           0 
  (4)   Took prohibited medication              9
n=43 Excluded from PP
  (1)   Major protocol violation                   9 
  (2)   Did not perform all walks
         on Day 1                                           26 
  (3)   No predose pain assessment          1
  (4)   Took prohibited medication            6
  (1) + (2)                                                      1
  (1) + (2)                                                      1
n=19 Excluded from PP
  (1)   Major protocol violation                 1 
  (2)   Did not perform all walks
         on Day 1                                         14 
  (3)   No predose pain assessment        0
  (4)   Took prohibited medication           1 
  (2) + (3)                                                     1
  Other                                                        1
N=179 N=165 N=92
Fig. 2. Patient disposition.
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on day 1
Two secondary efﬁcacy end points were measured on
day 1. Time-speciﬁc PID VAS scores were derived by
subtracting PI scores at 0.5, 1, 1.5, 2, 3, 4, 5, and 6 h after
the ﬁrst dose of study drug administration from the baseline
PI score, represented by pain after the ﬁrst 10-min walk.
Summed PID VAS at 6 h (SPID-6) was calculated from
the area under the timeeeffect PID curve using the trape-
zoidal rule.
Onset of analgesia (with walking) was deﬁned as
a 25% reduction in PI from baseline. In a post hoc anal-
ysis, the time-speciﬁc incidence of the above-deﬁned an-
algesic onset at 1, 2, 3, 4, 5, and 6 h after the ﬁrst dose
of study medication was derived for each treatment group
using post hoc logistic regression analysis. In addition,
the median time to ﬁrst onset of analgesia was deter-
mined for each treatment group by the Kaplan Meier
estimate.
The intent-to-treat (ITT) cohort contained patients who
were randomized and received at least one dose of study
medication. The assessable population for the onset of an-
algesia end points, designated as PP (per protocol) cohort,
was used to analyze PID scores, SPID-6, the time-speciﬁc
incidence of onset of analgesia with walking, and median
time to ﬁrst onset of analgesia. Speciﬁcally, the PP popula-
tion contained patients in the ITT population who completed
each of the required 10 1 min walks before each PI
assessment on day 1. In addition, the PP population
contained patients in the ITT cohort who had no major
preexisting protocol violations, completed a predose PIassessment, and had not taken any prohibited medications
on day 1.
Results
PATIENT DISPOSITION
Patient disposition is summarized in Fig. 2. In total, 530
patients were randomized to receive valdecoxib 10 mg qd
(n¼ 212), rofecoxib 25 mg qd (n¼ 208), or placebo
(n¼ 110). All patients who were randomized received at
least one dose of study medication, and were, therefore,
included in the ITT population.
The PP cohort (assessable for onset of analgesia end
points on day 1) included 435 patients (179 valdecoxib-,
165 rofecoxib-, and 91 placebo-treated patients). A total of
95 patients were excluded from the PP population for one or
more reasons (Fig. 2). Most of these patients (62/95 [65%])
were excluded because they did not complete all of the
10 1 min walks before each PI VAS assessment on
day 1. Other reasons for exclusion were major preexisting
protocol violation (17/95 [18%]), prohibited medication
taken on day 1 (16/95 [17%]), no predose PI assessment
(2/95 [2%]), and no informed consent form (1/95 [1%]).
There were no signiﬁcant differences between treatment
groups with respect to baseline patient demographics or OA
assessments at screening (Table I). Patients’ mean age
was 63e65 years, and the mean duration of OA was
7.5e8.1 years (Table I). The percent of patients taking
low-dose aspirin was similar in patients taking valdecoxib
(n¼ 38/212, 17.9%), rofecoxib (n¼ 49/208, 23.6%), and
placebo (n¼ 26/110, 23.6%).Table I
Baseline demographics and OA assessments at screening of all patients
Valdecoxib, 10
mg qd (n¼ 212)
Rofecoxib, 25
mg qd (n¼ 208)
Placebo (n¼ 110) P value
Age, years 0.33
Mean (SD) 63.3 (8.9) 64.6 (9.4) 63.9 (9.2)
Range 50e91 49e93 50e83
Female, n (%) 133 (63) 137 (66) 73 (66) 0.74
Race, n (%) 0.95
Caucasian 159 (75) 155 (75) 84 (76)
Black 42 (20) 47 (23) 22 (20)
Asian 3 (1.4) 1 (0.5) 0
Other 8 (3.8) 5 (2.4) 4 (3.6)
Duration of OA, years 0.68
Mean (SD) 8.1 (7.7) 8.1 (8.1) 7.5 (7.0)
Functional capacity, n (%)* 0.91
Class I 6 (3) 9 (4) 3 (3)
Class II 185 (87) 176 (85) 95 (86)
Class III 21 (10) 23 (11) 12 (11)
OA ﬂare category, n (%)y 0.33
Category 1 172 (81) 178 (86) 88 (80)
Category 2 40 (19) 30 (14) 22 (20)
Prescreening OA NSAIDs/
analgesics taken, n (%)
0.64
None 38 (17.9) 32 (15.4) 21 (19.1)
Nonspeciﬁc NSAIDs 68 (32.1) 93 (44.7) 35 (31.8)
COX-2 speciﬁc inhibitors 84 (39.6) 69 (33.2) 34 (30.9)
Analgesic agents 53 (25.0) 50 (24.0) 41 (37.3)
*Class I: Complete functional capacity with ability to carry on all usual duties without handicaps; Class II: functional capacity adequate to
conduct normal activities despite handicap of discomfort or limited mobility of one or more joints; Class III: functional capacity adequate to
perform only few or none of the duties of usual occupation or self-care.
yCategory 1: Patients were previously receiving NSAIDs or analgesic therapy for their OA; Category 2: patients’ OA was not controlled and
they were not previously receiving any OA treatment.
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OA symptoms of all randomized patients during the period of flare
Valdecoxib, 10 mg qd
(n¼ 212)
Rofecoxib, 25 mg qd
(n¼ 208)
Placebo
(n¼ 110)
P value
Patient’s assessment of OA pain
VAS, mean (SD), mm
Screening 52.3 (23.8) 52.5 (23.0) 55.2 (22.0) 0.48
Baseline 71.8 (16.4) 70.9 (17.0) 73.7 (16.0) 0.18
Lequesne OA severity index (range 0e24)
Screening 12.7 (3.3) 12.8 (3.6) 12.9 (3.6) 0.83
Baseline 15.3 (3.3) 15.3 (3.2) 15.4 (3.5) 0.92
Patients’ global assessment of arthritis (%)
Screening: 0.96
Good/very good 58 (27) 57 (27) 29 (26)
Fair 114 (54) 112 (54) 62 (56)
Poor/very poor 40 (18) 39 (19) 19 (18)
Baseline: 0.73
Good/very good 0 0 0
Fair 57 (27) 60 (29) 34 (31)
Poor/very poor 155 (73) 148 (71) 76 (69)
Physicians’ global assessment of arthritis (%)
Screening: 0.54
Good/very good 59 (27) 61 (29) 24 (22)
Fair 127 (60) 128 (62) 76 (69)
Poor/very poor 26 (12) 19 (9) 10 (9)
Baseline: 0.80
Good/very good 0 1 (<1) 0
Fair 63 (30) 65 (31) 31 (28)
Poor/very poor 149 (70) 142 (68) 79 (72)OA flare at baseline
During the period between screening and baseline,
patients experienced a marked increase in the severity of
their OA symptoms, with no signiﬁcant differences observed
among the treatment groups (Table II). Patients’ assess-
ment of OA pain VAS increased markedly across treatment
groups from means of 52e55 mm at screening, to means of
71e74 mm at baseline (Fig. 3; Table II). Modiﬁed OA sever-
ity index increased on the 0e24 scale from 13 at screening
to 15 at baseline.At the screening assessment, 26e27% of patients rated
their global disease assessment as good or very good. After
discontinuing NSAID or analgesic agents, none of the
patients rated their disease as good or very good at base-
line. The percentage of patients who rated their disease
as poor or very poor increased markedly from screening
(18e19%) to the baseline assessment (69e73%). Results
for the physicians’ global assessment of OA disease at
screening and baseline matched those of the patients’
assessment (Table II).Fig. 3. Time-speciﬁc PID VAS on day 1 in the PP1 population. *P 0.05, yP< 0.01, zP< 0.001 vs placebo.
1116 R. W. Moskowitz et al.: Osteoarthritis acute pain modelFig. 4. Time-speciﬁc incidence of onset of analgesia, deﬁned as a 25% PI reduction from baseline, during the ﬁrst 6 h in the PP population.
*P 0.05, yP< 0.01, zP< 0.001 vs placebo.ONSET OF ANALGESIA WITH WALKING
In the PP cohort, PID VAS scores were signiﬁcantly
greater with both active treatments vs placebo beginning
at 4 h with valdecoxib, and 5 h with rofecoxib (P 0.05)
(Fig. 3).
Figure 4 shows the time-speciﬁc incidence of all patients
with respect to onset of analgesia (i.e., 25% reduction in PI)
from 1 to 6 h after the ﬁrst dose of study medication in the
PP population. By 4 h, the percentage of patients with anal-
gesic onset was signiﬁcantly higher in both valdecoxib
(60%) and rofecoxib (57%) groups compared with placebo
(42%; P¼ 0.008 vs valdecoxib; P¼ 0.028 vs rofecoxib).
The median time to ﬁrst onset of analgesia in the PP cohort
was signiﬁcantly shorter for both valdecoxib (2 h; 95% Con-
ﬁdence Interval (CI) 2.0, 3.0) and rofecoxib (2 h; 95% CI):
2.0, 3.0) compared with placebo (4 h; 95% CI: 2.0, 6 h;
P¼ 0.088 vs valdecoxib; P¼ 0.075 vs rofecoxib).
Valdecoxib provided a signiﬁcantly improved SPID score
in the ﬁrst 6 h in the PP cohort, compared with that seen in
the placebo group (122.4 10.3 vs 81.0 14.4; P< 0.05).
In contrast, the SPID-6 score in rofecoxib-treated patients
was not signiﬁcantly different from that seen with placebo
(104.5 10.1 vs 81.0 14.4; P¼ 0.098). The difference in
SPID-6 between valdecoxib and rofecoxib, however, was
not statistically signiﬁcant.
The analgesic onset results with the PP cohort are
supported by the ITT population. Compared with placebo,
PID VAS scores were signiﬁcantly greater from 3 h with
both valdecoxib and rofecoxib (P< 0.05) (Table III).
Table III
Time-specific PID VAS on day 1 in the ITT population, mean
Standard Error of the Mean (S.E.M.)
Time (h) Valdecoxib,
10 mg qd
(n¼ 212)
Rofecoxib,
25 mg qd
(n¼ 208)
Placebo
(n¼ 110)
0.5 5.54 1.1 3.09 1.1 5.54 1.4
1.0 9.39 1.3 7.30 1.3 8.8 2.0
1.5 14.95 1.6 11.77 1.5 11.33 2.3
2.0 18.70 1.8 15.33 1.7 13.87 2.5
3.0 21.65 2.0* 19.75 1.8* 15.49 2.8
4.0 24.94 1.9** 22.79 1.9** 16.73 2.6
5.0 26.64 2.0*** 25.16 2.0*** 16.87 2.7
6.0 28.97 2.0*** 27.97 2.0*** 16.48 2.8
*P< 0.05, **P< 0.01, ***P< 0.001 vs placebo.In the ITT population, the percentage of patients with
onset of analgesia was signiﬁcantly higher relative to
placebo from 4 h for both valdecoxib (55%) and rofecoxib
(56%) compared with placebo (40%); P¼ 0.015 vs valde-
coxib; P¼ 0.008 vs rofecoxib.
Median time to ﬁrst onset of analgesia in the ITT popula-
tion including all participants was shorter with both valde-
coxib (3 h; 95% CI: 2.0, 4.0) and rofecoxib (3 h; 95% CI:
2.0, 3.0) compared with placebo 4 h (95% CI: 2.0, >6.0;
P¼ 0.104 vs valdecoxib; P¼ 0.036 vs rofecoxib) (Table IV).
SAFETY
One serious adverse event was reported about 8 days
into a 2-week extension of this study: a case of cardiac
failure in a male patient, aged 81 years, taking valdecoxib.
The event was considered severe and required hospitaliza-
tion. The patient had a history of coronary artery disease,
and had discontinued furosemide 2 months prior to the
study without his cardiologist’s advice. The investigator
believed that there was a reasonable possibility that the
events were related to a combination of the patient discon-
tinuing his cardiac medication in July 2002 and the initiation
of valdecoxib treatment.
Discussion
An analgesic model has been developed that represents
a paradigm shift for the study of OA. OA response to
Table IV
Percent incidence of onset of analgesia, defined as a 25% PI
reduction from baseline, during the first 6 h in the ITT population
Time
(h)
Valdecoxib,
10 mg qd
(n¼ 212)
Rofecoxib,
25 mg qd
(n¼ 208)
Placebo
(n¼ 110)
1.0 29 25 28
2.0 46 46 39
3.0 50 54* 41
4.0 55* 56** 40
5.0 56* 60** 42
6.0 58* 66*** 43
*P< 0.05, **P< 0.01, ***P< 0.001 vs placebo.
1117Osteoarthritis and Cartilage Vol. 14, No. 11therapy can be considered using two different models: the
classic OA study model is a disease management model
that focuses on chronic care of a chronic disease, with
long-term outcome assessments. A complementary model,
as described in this study, focuses on OA ﬂare, and is an
acute pain model in which onset of analgesia is the primary
outcome target. This latter model is clinically relevant
because many patients with OA are treated primarily during
periods of ﬂare. It has been suggested that NSAIDs should
be used for the shortest duration needed, which may
increase intermittent use; accordingly, rapid onset of action
would be especially beneﬁcial. Such patients are seeking
rapid relief from an acute exacerbation of chronic OA
pain; repeated delays in pain relief may lead to peripheral
and central sensitization, and a worsening of chronic pain2.
In the present study, the analgesic model of OA ﬂare al-
lowed separation in PI reductions from placebo with two
COX-2 speciﬁc inhibitors, valdecoxib 10 mg and rofecoxib
25 mg, known to have analgesic activity in OA with the abil-
ity to estimate median time to onset at 30 min intervals. A
signiﬁcant difference vs placebo in PI reductions from base-
line occurred on day 1 as early as 3 h after the ﬁrst dose of
treatment. In a post hoc analysis, the incidence of patients
with onset of analgesia with walking (deﬁned as a 25%
reduction in PI from baseline) was signiﬁcantly higher after
4 h postdose for valdecoxib or rofecoxib compared with
placebo. The median time to ﬁrst onset of analgesia in the
assessable population was signiﬁcantly shorter for both
active treatments (2 h) compared with placebo (4 h).
A substantial placebo response was noted, especially in
the ﬁrst 3e4 h (Fig. 4). A high placebo response rate is
also typically seen in OA studies of longer duration that
focus on chronic disease management. The onset times
for differences in PID VAS for valdecoxib and rofecoxib vs
placebo in this study are substantially longer than observed
with valdecoxib 40 mg (30 min) and rofecoxib 50 mg
(45 min) in oral surgery acute pain trials6,7. This marked dif-
ference in onset of response in acute dental pain and pain
associated with the OA ﬂare may be due to differences in
the etiology of pain in the two entities, or differences be-
tween the OA and dental pain models.
Other acute pain models assessing analgesic onset with
COX-2 speciﬁc inhibitors in OA of the knee have recently
been described16,17. In the present model, treatment com-
mences following a period of OA ﬂare, and patients assess
their PI VAS during the ﬁrst 6 h following medication on day
1. Each pain assessment is made following a 10-min walk
on a ﬂat surface. End points during the ﬁrst 6 h postdose
are time-speciﬁc PID VAS and SPID-6. In another analgesic
model16, eligible patients are required to have pain in their
target knee of 50 mm VAS after walking 20 paces on
a ﬂat surface. The primary end point was PID VAS at 3
and 5 h after the ﬁrst dose of study medication. Results
showed that PID VAS at 3 and 5 h was signiﬁcantly greater
in patients randomized to lumiracoxib 400 mg (19.8 mm)
compared with those taking placebo (13.4 mm; P¼ 0.004).
In a different model17, onset of symptom relief was eval-
uated in patients with OA of the knee in ﬂare at 4 h after the
ﬁrst dose of treatment, and daily over 6 days, using a cate-
gorical scale, Patient Global Assessment of Response to
Therapy (PGART). In addition, reduction in pain with walk-
ing on a ﬂat surface was assessed using WOMAC VAS
from Question 1 of the WOMAC Pain Scale from 28 h after
the ﬁrst dose of treatment, and daily over 6 days. Results
have been presented in two identically designed studies
of patients randomized to rofecoxib 12.5 mg, the nonspe-
ciﬁc NSAID nabumetone 1000 mg, or placebo. From 4 hon day 1 to day 6, a signiﬁcantly greater proportion of rofe-
coxib-treated patients had a PGART response of good or
excellent compared with those taking nabumetone or
placebo (P< 0.001). Reduction in pain VAS with walking
on a ﬂat surface was also signiﬁcantly greater with rofecoxib
(27.4) compared with nabumetone (21.6) and placebo
(14.0; P< 0.001) from 28 h on day 1 to day 6.
An important aspect of the present analgesic model is
that patients with knee OA ﬂare assessed their pain VAS
following a prescribed 10-min walk. This walk is designed
to reﬂect a common, ‘‘real world’’, function-oriented activity,
which typically causes knee OA joint pain. However,
a potential confounder in the present trial was the lack of
control for the rate of walking. As patients experience in-
creasing pain, they may compensate by walking more
slowly. A slower walk may reduce pain, thereby decreasing
patients’ assessment of pain VAS. Thus, future study
designs may be improved by accounting for patients’ rate
of walking, distance, and length of time walked.
In conclusion, a clinically relevant analgesic model of
knee OA ﬂare has been assessed in a study comparing
analgesic onset (with walking) with valdecoxib 10 mg qd,
rofecoxib 25 mg qd, and placebo. The model effectively
demonstrated PI reductions from baseline vs placebo
following a prescribed walk on day 1 as early as 4e5 h after
the ﬁrst dose of treatment. Although other models for pain
assessment have been described, this model allows as-
sessment of pain relief responses within hours rather than
days or weeks when evaluating analgesic efﬁcacy in OA.
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